GSK Pharma Receives NPPA Demand Notice of Rs 3.54 Crore, Plans to Appeal:

GSK Pharma has received a Rs 3.54 crore demand notice from the NPPA over alleged overcharging of scheduled formulations and plans to appeal.

NPPA Issues Rs 3.54 Cr Notice to GSK Pharma

Vanshika verma

Jun 26, 2026

Last update on Jun 26, 2026

GSK Pharma Receives NPPA Demand Notice of Rs 3.54 Crore, Plans to Appeal GlaxoSmithKline Pharmaceuticals Ltd (GSK Pharma) has received a demand notice of Rs. 3,54,12,025 from the National Pharmaceutical Pricing Authority (NPPA), according to a stock exchange filing made on June 25, 2026. The notice, dated June 24, 2026, alleges that the company overcharged customers by selling certain scheduled medicines at prices higher than those fixed by the government. The total demand is Rs. 3,54,12,025 including alleged overcharging, Rs. 1,22,91,163 and interest Rs. 2,31,20,862. GSK Pharma said it received the notice on June 24, 2026. The company clarified that the demand will not have any impact on its financial operations. The company also stated that it plans to file an appeal against the demand notice. The company made the above disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

About Author

Vanshika verma

Content Writer

Vanshika Verma is a Content Writer with 1+ year of experience at Studycafe.in. A B.Com graduate from Delhi University, She writes articles on Finance, Tax, ICAI, GST, and the latest financial news, with a focus on making complex topics easy for readers and professionals.